Payment overview · 2025
General Payments
$2,172.03
94 reported records · 27 companies
Healthcare provider profile · identity verified
Leon E Schwechter, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · GREENVALE, NY · NPI 1225078314
Verified facts
What the public records show
CMS Open Payments records show Leon E Schwechter, D.O. received $2,172.03 in general payments during 2025 across 94 reported records.
Amgen Inc. accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexlizet by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $595.65 | 27.4% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $258.72 | 11.9% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $186.28 | 8.6% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.24 | 8.0% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $163.38 | 7.5% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $162.31 | 7.5% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $74.90 | 3.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $72.72 | 3.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.70 | 2.8% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $52.09 | 2.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $34.08 | 1.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.36 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.48 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.28 | 1.3% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $25.93 | 1.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.56 | 1.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $24.20 | 1.1% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $23.27 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.23 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.15 | 0.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.00 | 0.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.04 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.65 | 0.8% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $16.61 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $15.75 | 0.7% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $15.41 | 0.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.04 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,172.03 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $486.14 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $189.50 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $162.31 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $157.88 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $143.43 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $133.99 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $109.51 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $101.00 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $80.26 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $77.41 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $77.41 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $74.90 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $59.72 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $59.72 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $59.72 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.70 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.38 | 4 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $52.09 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $49.15 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $34.08 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $31.55 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $29.39 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.48 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.48 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 70 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 22 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
73 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
181 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 543 | 166 |
| Mounjaro | Tirzepatide | 304 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 263 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 65 |
| Ozempic | Semaglutide | 181 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 64 |
| Sertraline Hcl | Sertraline Hcl | 159 | 42 |
| Ezetimibe | Ezetimibe | 125 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 33 |
| Lisinopril | Lisinopril | 106 | 32 |
| Gabapentin | Gabapentin | 105 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 29 |
| Finasteride | Finasteride | 94 | 19 |
| Losartan Potassium | Losartan Potassium | 91 | 35 |
| Omeprazole | Omeprazole | 87 | 28 |
| Trazodone Hcl | Trazodone Hcl | 87 | 20 |
| Pregabalin | Pregabalin | 86 | 21 |
| Synthroid | Levothyroxine Sodium | 82 | 20 |
| Allopurinol | Allopurinol | 80 | 23 |
| Meloxicam | Meloxicam | 80 | 27 |
| Alprazolam | Alprazolam | 79 | 32 |
| Valsartan | Valsartan | 76 | 22 |
| Metformin Hcl | Metformin Hcl | 75 | 24 |
| Furosemide | Furosemide | 74 | 29 |
| Xarelto | Rivaroxaban | 73 | 20 |
| Jardiance | Empagliflozin | 72 | 22 |
| Eliquis | Apixaban | 70 | 26 |
| Metformin Hcl Er | Metformin Hcl | 70 | 21 |
| Indapamide | Indapamide | 65 | 23 |
| Bupropion Xl | Bupropion Hcl | 64 | 18 |
| Potassium Chloride | Potassium Chloride | 62 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 16 |
| Atenolol | Atenolol | 57 | 16 |
| Buspirone Hcl | Buspirone Hcl | 54 | 15 |
| Gemtesa | Vibegron | 54 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 18 |
| Midodrine Hcl | Midodrine Hcl | 51 | 14 |
| Donepezil Hcl | Donepezil Hcl | 50 | 17 |
| Simvastatin | Simvastatin | 50 | 19 |
| Lorazepam | Lorazepam | 47 | 16 |
| Montelukast Sodium | Montelukast Sodium | 47 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | 15 |
| Aripiprazole | Aripiprazole | 43 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 16 |
| Famotidine | Famotidine | 42 | 14 |
| Mirtazapine | Mirtazapine | 42 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 19 |
| Ramipril | Ramipril | 39 | suppressed |
| Irbesartan | Irbesartan | 38 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Carvedilol | Carvedilol | 30 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Torsemide | Torsemide | 29 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Ramelteon | Ramelteon | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Digoxin | Digoxin | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Tadalafil | Tadalafil | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Valium | Diazepam | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Matzim La | Diltiazem Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,172.03 · 94 records | Amgen Inc. | ABRYSVO, AFREZZA, AREXVY, BOTOX, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, INSPIRE, JARDIANCE, Kerendia, LEQVIO, LUNA, Leqembi, MYFEMBREE, NEXLETOL, NURTEC ODT, OTEZLA, PAXLOVID, PREVNAR 20, QULIPTA, RECORLEV, REPATHA, REXULTI, REZDIFFRA, SHINGRIX, SPRAVATO, UBRELVY, VOWST, VRAYLAR, Wegovy, Yorvipath | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error